Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436163 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL26363085 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2ALDH1A1MEN1KMT2ATP53 | |
| SCHEMBL29436224 | 0.86 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL23495418 | 0.86 | ALDH1A1 (0.54) | SMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL23495271 | 0.86 | ALDH1A1 (0.59) | SMN1; SMN2ALDH1A1TP53MAPT | |
| SCHEMBL23495178 | 0.85 | MAPT (0.49) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL29436219 | 0.85 | MAPT (0.49) | ALDH1A1MEN1KMT2ATP53MAPT | |
| SCHEMBL29436225 | 0.84 | TP53 (0.60) | SMN1; SMN2ALDH1A1L3MBTL1TP53MAPT | |
| SCHEMBL23495355 | 0.84 | TP53 (0.60) | SMN1; SMN2ALDH1A1L3MBTL1TP53MAPT | |
| SCHEMBL23495109 | 0.80 | MEN1 (0.58) | ALDH1A1MEN1KMT2ATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248972-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4248972-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3877052-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-3877052-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPECUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| WO-2021231546-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179579-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | SMN1; SMN2 9/4885ALDH1A1 270/4885L3MBTL1 4133/4885 |
| US-20230293518-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | SMN1; SMN2 3/4885ALDH1A1 308/4885L3MBTL1 3930/4885 |
| US-11236065-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | SMN1; SMN2 9/4885ALDH1A1 270/4885L3MBTL1 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.